SCHEMBL21775670

SCHEMBL21775670

CC(C)(C)OC(=O)N(C1CCNCC1)[C@H]1C[C@H]1c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 3/20 0.41
MAOB P27338 1/20 0.41
EZH2 Q15910 2/20 0.39
SLC6A4 P31645 7/20 0.39
SLC6A2 P23975 6/20 0.39
SLC6A3 Q01959 5/20 0.39
CYP2D6 P10635 3/20 0.39
MAOA P21397 1/20 0.39
CHRM3 P20309 1/20 0.38
KCNH2 Q12809 1/20 0.38
MAPT P10636 1/20 0.38
PKM P14618 1/20 0.38
SSTR1 P30872 1/20 0.38
SSTR4 P31391 1/20 0.38
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
CISD1 Q9NZ45 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23867768 1.00 KDM1A (0.41) KDM1AMAOBEZH2SLC6A4SLC6A2
SCHEMBL19091464 1.00 KDM1A (0.41) KDM1AMAOBEZH2SLC6A4SLC6A2
SCHEMBL21784349 1.00 KDM1A (0.41) KDM1AMAOBEZH2SLC6A4SLC6A2
SCHEMBL18817746 1.00 KDM1A (0.41) KDM1AMAOBEZH2SLC6A4SLC6A2
SCHEMBL18817744 1.00 KDM1A (0.41) KDM1AMAOBEZH2SLC6A4SLC6A2
SCHEMBL19025431 0.86 KDM1A (0.39) KDM1AMAOBEZH2SLC6A4SLC6A2
SCHEMBL28272985 0.86 KDM1A (0.41) KDM1AMAOBEZH2MAOAHDAC8
SCHEMBL20134529 0.85 SLC6A2 (0.42) KDM1AMAOBSLC6A4SLC6A2SLC6A3
SCHEMBL19609147 0.83 KDM1A (0.42) KDM1AMAOBSLC6A4SLC6A2SLC6A3
SCHEMBL23856027 0.82 KDM1A (0.43) KDM1AMAOBSLC6A4SLC6A2MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11512064-B2 Salts of an LSD1 inhibitor and processes for preparing the same INCYTE CORPORATION (US) 2022-11-29 US disclosed
US-10968200-B2 Salts of an LSD1 inhibitor and processes for preparing the same INCYTE CORPORATION (US) 2021-04-06 US disclosed
US-20200071289-A1 SALTS OF AN LSD1 INHIBITOR AND PROCESSES FOR PREPARING THE SAME WILMINGTON PHARMATECH 2020-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11512064-B2 Salts of an LSD1 inhibitor and processes for preparing the same KDM1A, KDM1B, KDM2A KDM1A 1/4885MAOB 386/4885EZH2 33/4885
US-20200071289-A1 SALTS OF AN LSD1 INHIBITOR AND PROCESSES FOR PREPARING THE SAME KDM1A, KDM1B, KDM2A KDM1A 1/4885MAOB 386/4885EZH2 33/4885
US-10968200-B2 Salts of an LSD1 inhibitor and processes for preparing the same KDM1A, KDM1B, KDM2A KDM1A 1/4885MAOB 386/4885EZH2 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.